Allarity Therapeutics to Present at Ladenburg Thalmann Healthcare Conference
Press release
Cambridge, MA U.S.A. (September 16, 2022) — Allarity Therapeutics, Inc. (Nasdaq:ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, announced that Chief Executive Officer James G. Cullem will deliver a corporate update and host investor 1×1 meetings at the Ladenburg Thalmann Healthcare Conference in New York, NY. Mr. Cullem’s presentation is scheduled for Thursday, September 29, 2022 at 3:00 p.m. ET at the Sofitel Hotel New York at Track 2 – St. Germain III.
Related news for (ALLR)
- Allarity Therapeutics Announces Participation in Pharma Partnering Summit US
- Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025
- Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares
- Today’s Top Performers: MoBot’s Market Review 03/19/25 03:00 PM
- Today’s Top Performers: MoBot’s Market Review 03/19/25 02:00 PM